Media stories about Fluidigm (NASDAQ:FLDM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.6973115534974 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress (finance.yahoo.com)
- Piper Jaffray Companies Reaffirms “Hold” Rating for Fluidigm (FLDM) (americanbankingnews.com)
- Fluidigm (FLDM) Releases Earnings Results, Beats Expectations By $0.17 EPS (americanbankingnews.com)
- Is Fluidigm Corporation (NASDAQ:FLDM) Undervalued? (finance.yahoo.com)
- Fluidigm Co. (FLDM) Insider Buys $307,185.30 in Stock (americanbankingnews.com)
FLDM has been the topic of several research reports. ValuEngine upgraded shares of Fluidigm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Piper Jaffray Companies restated a “hold” rating and issued a $6.10 price target on shares of Fluidigm in a research report on Thursday.
Shares of Fluidigm (NASDAQ:FLDM) traded up $0.80 on Monday, reaching $6.58. 703,300 shares of the company traded hands, compared to its average volume of 187,980. Fluidigm has a 12 month low of $2.52 and a 12 month high of $7.05. The company has a market capitalization of $254.30, a PE ratio of -3.46 and a beta of 3.24. The company has a debt-to-equity ratio of 5.00, a current ratio of 3.02 and a quick ratio of 2.46.
Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Fluidigm had a negative return on equity of 116.02% and a negative net margin of 59.38%. The business had revenue of $27.75 million during the quarter, compared to the consensus estimate of $27.14 million. During the same quarter in the prior year, the firm posted ($0.32) EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. analysts anticipate that Fluidigm will post -0.7 earnings per share for the current year.
In other news, insider Levin Capital Strategies, L.P. acquired 20,380 shares of the business’s stock in a transaction on Wednesday, November 29th. The shares were acquired at an average price of $5.71 per share, for a total transaction of $116,369.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 482,624 shares of company stock worth $2,917,895 in the last 90 days. 4.70% of the stock is currently owned by company insiders.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.